🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 46 of 116

  1. Ensartinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. Ensartinib

    The First People's Hospital of Lianyungang

    Solid Tumors

    phase 2 small molecule active

    1 trial

  3. Entinostat

    Syndax Pharmaceuticals

    Lymphoma

    phase 2 small molecule active

    1 trial

  4. Entinostat

    KYOWA KIRIN AUSTRALIA PTY LTD

    Advanced or Recurrent Breast Cancer

    phase 2 small molecule completed

    1 trial

  5. Entinostat

    Syndax Pharmaceuticals

    Melanoma

    phase 2 small molecule completed

    1 trial

  6. Entinostat

    Syndax Pharmaceuticals

    ER+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  7. Entinostat

    Syndax Pharmaceuticals

    Hodgkin's Lymphoma

    phase 2 small molecule terminated

    1 trial

  8. Entinostat

    Syndax Pharmaceuticals

    Metastatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  9. Entinostat

    Syndax Pharmaceuticals

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    2 trials

  10. Entinostat

    Syndax Pharmaceuticals

    Non-Small-Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  11. Entinostat

    Syndax Pharmaceuticals

    Renal Cell Carcinoma

    phase 2 small molecule active

    2 trials

  12. Entrectinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule active

    1 trial

  13. Entrectinib

    Hoffmann-La Roche

    Breast Cancer

    phase 2 small molecule active

    1 trial

  14. Envafolimab

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  15. Envafolimab

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  16. Envafolimab Injection

    The First People's Hospital of Lianyungang

    Gastrointestinal Neoplasms

    phase 2 small molecule active

    1 trial

  17. Enzalutamide

    BRIGHT MINDS BIOSCIENCES INC.

    Prostate Cancer Metastatic

    phase 2 small molecule completed

    1 trial

  18. Enzalutamide

    CORCEPT THERAPEUTICS INC

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  19. Enzalutamide 40mg

    United Therapeutics Europe Ltd

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  20. Epcoritamab

    ADC Therapeutics SA

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  21. Epcoritamab

    United Therapeutics Europe Ltd

    Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

    phase 2 mab active

    1 trial

  22. Epcoritamab, Epcoritamab, PARACETAMOL , ANAKINRA , LENALIDOMIDE , DEXAMETHASONE , DIPHENHYDRAMINE , SILTUXIMAB , TOCILIZUMAB

    Genmab A/S

    DIFFUSE LARGE B CELL LYMPHOMA

    phase 2 small molecule active

    1 trial

  23. Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  24. Erbitux 5 mg/mL solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    The George Institute

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  25. Erdafitinib Intravesical Delivery System

    Janssen Cilag International NV

    Non-Muscle Invasive Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  26. Eribulin mesylate

    HALOZYME THERAPEUTICS, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  27. Erlotinib

    Solid Biosciences

    Leptomeningeal Carcinomatosis

    phase 2 small molecule terminated

    1 trial

  28. Erlotinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  29. Erlotinib

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  30. Erlotinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  31. Erlotinib

    United Therapeutics Europe Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  32. Erlotinib

    Hoffmann-La Roche

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  33. Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

    phase 2 small molecule terminated

    1 trial

  34. EstroTep 500 MBq/mL, solution injectable, ELACESTRANT, EXEMESTANE, ELACESTRANT

    Istituto Gentili S.r.l.

    Metastatic hormone receptor-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  35. Etigilimab

    Mereo BioPharma Group plc

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  36. Etoposide

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  37. Etoposide 20 mg/ml Concentrate for solution for infusion , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion., ADRIBLASTINE 10 mg, poudre pour solution injectable en flacon, Cyclophosphamide Sandoz, 100 mg/mL, koncentrat do sporządzania roztworu do wstrzykiwań / do infuzji

    Ningbo Cancer Hospital

    Patients with a confirmed diagnosis of ovarian small cell carcinoma.

    phase 2 small molecule active

    1 trial

  38. Etrumadenant

    Arcus Biosciences

    Prostatic Neoplasms, Castration-Resistant

    phase 2 small molecule completed

    1 trial

  39. Etrumadenant (AB928)

    Arcus Biosciences

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  40. Etrumadenant, Quemliclustat, FLUOROURACIL, BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, Zimberelimab, Etrumadenant, REGORAFENIB

    Arcus Biosciences

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  41. Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 other active

    1 trial

  42. Everolimus

    Takeda

    Clear-cell Metastatic Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  43. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Microsatellite Stable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  44. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer, Metastatic

    phase 2 small molecule active

    1 trial

  45. Exercise Training

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 other completed

    1 trial

  46. Exicorilant

    CORCEPT THERAPEUTICS INC

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  47. Expanded , Activated NK cells

    Hospital Authority, Hong Kong

    Ewing Sarcoma

    phase 2 mab active

    1 trial

  48. Experimental

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer (LARC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.